Brendan Smith
Stock Analyst at TD Cowen
(1.62)
# 3,032
Out of 4,831 analysts
6
Total ratings
40%
Success rate
0.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brendan Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNA Ginkgo Bioworks Holdings | Maintains: Buy | $3 → $10 | $8.18 | +22.25% | 1 | Sep 20, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $59 → $65 | $49.67 | +30.86% | 2 | Aug 7, 2024 | |
| NVAX Novavax | Maintains: Hold | $5 → $10 | $6.28 | +59.24% | 1 | May 13, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Outperform | n/a | $15.60 | - | 1 | Jul 21, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | n/a | $14.10 | - | 1 | Dec 5, 2022 |
Ginkgo Bioworks Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $3 → $10
Current: $8.18
Upside: +22.25%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Buy
Price Target: $59 → $65
Current: $49.67
Upside: +30.86%
Novavax
May 13, 2024
Maintains: Hold
Price Target: $5 → $10
Current: $6.28
Upside: +59.24%
Arrowhead Pharmaceuticals
Jul 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $15.60
Upside: -
Denali Therapeutics
Dec 5, 2022
Initiates: Outperform
Price Target: n/a
Current: $14.10
Upside: -